These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27864345)

  • 1. PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.
    Lacey A; Rodrigues-Hoffman A; Safe S
    Cancer Res; 2017 Feb; 77(3):732-741. PubMed ID: 27864345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS).
    Lacey A; Hedrick E; Li X; Patel K; Doddapaneni R; Singh M; Safe S
    Oncotarget; 2016 May; 7(21):31257-69. PubMed ID: 27144436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma.
    Kikuchi K; Hettmer S; Aslam MI; Michalek JE; Laub W; Wilky BA; Loeb DM; Rubin BP; Wagers AJ; Keller C
    PLoS Genet; 2014 Jan; 10(1):e1004107. PubMed ID: 24453992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
    Tonelli R; McIntyre A; Camerin C; Walters ZS; Di Leo K; Selfe J; Purgato S; Missiaglia E; Tortori A; Renshaw J; Astolfi A; Taylor KR; Serravalle S; Bishop R; Nanni C; Valentijn LJ; Faccini A; Leuschner I; Formica S; Reis-Filho JS; Ambrosini V; Thway K; Franzoni M; Summersgill B; Marchelli R; Hrelia P; Cantelli-Forti G; Fanti S; Corradini R; Pession A; Shipley J
    Clin Cancer Res; 2012 Feb; 18(3):796-807. PubMed ID: 22065083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness.
    Thuault S; Hayashi S; Lagirand-Cantaloube J; Plutoni C; Comunale F; Delattre O; Relaix F; Gauthier-Rouvière C
    Oncogene; 2013 Apr; 32(15):1876-87. PubMed ID: 22710718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells.
    Yoshida H; Miyachi M; Sakamoto K; Ouchi K; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Imamura T; Iehara T; Kakazu N; Hojo H; Hosoi H
    Oncogene; 2014 Dec; 33(49):5601-8. PubMed ID: 24213582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nuclear orphan receptor NR4A1 regulates β1-integrin expression in pancreatic and colon cancer cells and can be targeted by NR4A1 antagonists.
    Hedrick E; Lee SO; Safe S
    Mol Carcinog; 2017 Sep; 56(9):2066-2075. PubMed ID: 28418095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells.
    Shrestha R; Mohankumar K; Jin UH; Martin G; Safe S
    Mol Cancer Ther; 2021 Mar; 20(3):612-622. PubMed ID: 33277444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
    Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
    Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration.
    Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S
    Mol Cell Biol; 2016 May; 36(9):1383-94. PubMed ID: 26929200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.
    Hedrick E; Li X; Cheng Y; Lacey A; Mohankumar K; Zarei M; Safe S
    Breast Cancer Res Treat; 2019 Aug; 177(1):29-40. PubMed ID: 31119568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma.
    Hedrick E; Mohankumar K; Lacey A; Safe S
    Mol Cancer Res; 2019 Nov; 17(11):2221-2232. PubMed ID: 31462501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
    Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM
    Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma.
    Bharathy N; Suriyamurthy S; Rao VK; Ow JR; Lim HJ; Chakraborty P; Vasudevan M; Dhamne CA; Chang KT; Min VL; Kundu TK; Taneja R
    J Pathol; 2016 Nov; 240(3):269-281. PubMed ID: 27453350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN.
    Li HG; Wang Q; Li HM; Kumar S; Parker C; Slevin M; Kumar P
    Cancer Lett; 2007 Aug; 253(2):215-23. PubMed ID: 17350164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2.
    Song Z; Gong B; Qu T; Chen Y; Zhao G; Jin Y; Zhao Q
    Biomed Pharmacother; 2024 Aug; 177():117126. PubMed ID: 38996706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
    de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
    Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the proximal promoter regions of the PAX3 and PAX7 genes.
    Möller E; Isaksson M; Mandahl N; Mertens F; Panagopoulos I
    Cancer Genet Cytogenet; 2007 Oct; 178(2):114-9. PubMed ID: 17954266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.
    Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S
    Endocr Relat Cancer; 2015 Oct; 22(5):831-40. PubMed ID: 26229035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.